FDA Extends PDUFA Date for Biohaven to Review Troriluzole for SCA Treatment The FDA has extended the PDUFA date for Biohaven's Troriluzole application aimed at treating Spinocerebellar Ataxia, a rare neurodegenerative disease.

FDA Extends PDUFA Date for Biohaven to Review Troriluzole for SCA Treatment #United_States #Biohaven #New_Haven #Troriluzole #Biohaven_Ltd

Biohaven Achieves Significant Milestones in First Quarter 2025 Amidst Economic Challenges Biohaven Ltd. reports promising financial results for Q1 2025, highlighting significant funding agreements and ongoing clinical developments amid economic uncertainties.

Biohaven Achieves Significant Milestones in First Quarter 2025 Amidst Economic Challenges #United_States #Biohaven #New_Haven #Troriluzole #Oberland_Capital

Biohaven Reports Key Developments and Financial Results for 2024, Highlighting Innovative Drug Applications Biohaven recently shared updates on its success in drug applications and their financial results for 2024, emphasizing the innovation in their treatments.

Biohaven Reports Key Developments and Financial Results for 2024, Highlighting Innovative Drug Applications #USA #Biohaven #New_Haven #BHV-1300 #Troriluzole

FDA Granting Priority Review for Biohaven's Troriluzole Marks a Milestone in Spinocerebellar Ataxia Treatment Biohaven's Troriluzole shows promising results in treating Spinocerebellar Ataxia, as the FDA grants Priority Review for its New Drug Application.

FDA Granting Priority Review for Biohaven's Troriluzole Marks a Milestone in Spinocerebellar Ataxia Treatment #United_States #Biohaven #New_Haven #Troriluzole #Spinocerebellar_Ataxia